The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes

Cornea

Volumn 31, Issue 11, 2012, Pages 1235-1239

  Liu, Xiaowei ^a   Wang, Shuran ^a   Kao, Andrew A ^b   Long, Qin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

dry eyes; HLA DR; inflammation; pranoprofen

Indexed keywords

HLA DR ANTIGEN; HYALURONIC ACID; PRANOPROFEN; PRANOPULIN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONJUNCTIVA; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; DRUG EFFECT; DRY EYE; EPITHELIUM CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR SURFACE DISEASE INDEX; OCULAR SURFACE STAINING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; TEAR FILM BREAK UP TIME; VISUAL SYSTEM PARAMETERS;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPYRANS; CONJUNCTIVA; DRUG COMBINATIONS; DRY EYE SYNDROMES; FEMALE; HLA-DR ANTIGENS; HUMANS; HYALURONIC ACID; MALE; OPHTHALMIC SOLUTIONS; PROPIONATES; PROSPECTIVE STUDIES; TEARS; VISCOSUPPLEMENTS;

EID: 84867399457     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31824988e5     Document Type: Article

References (33)

1. Schaumberg DA, Sullivan DA, Buring JA, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
2. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007;5:75-92.
3. Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94:1312-1315.
4. Kymionis GD, Bouzoukis DI, Diakonis VF, et al. Treatment of chronic dry eye: Focus on cyclosporine. Clin Ophthalmol. 2008;2:829-836.
5. Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 2011;27:23-27.
6. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011;12:325-334.
7. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992;36:259-284.
8. Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J. 2008;10:229-241.
9. Akyol-Salman I, Leçe-Sertöz D, Baykal O. Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J Ocul Pharmacol Ther. 2007;23:280-283.
10. Notivol R, Martínez M, Bergamini MV. Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol. 1994;117:651-656.
11. Hashimoto T, Igarashi A, Hoshina F, et al. Effects of nonsteroidal antiinflammatory drugs on experimental allergic conjunctivitis in Guinea pigs. J Ocul Pharmacol Ther. 2003;19:569-577.
12. Hayasaka Y, Hayasaka S, Zhang XY, et al. Effects of topical antiinflammatory and antiallergic eyedrops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits. Arch Ophthalmol. 2002; 120:950-953.
13. Vitale S, Goodman LA, Reed GF, et al. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes. 2004;2:44.
14. Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. Am J Ophthalmol. 2010;149:405-415.
15. Barabino S, Montaldo E, Solignani F, et al. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010;91:524-529.
16. Sánchez MA, Arriola-Villalobos P, Torralbo-Jiménez P, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: A flow cytometric study. Eye (Lond). 2010;24:1331-1337.
17. Sanchez MA, Torralbo-Jimenez P, Giron N, et al. Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: A flow cytometric study. Cornea. 2010;29:167-1671.
18. Rolando M, Barabino S, Mingari C, et al. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes. Cornea. 2005;24:951-954.
19. Chandler JW, Gillette TE. Immunologic defense mechanisms of the ocular surface. Ophthalmology. 1983;90:585-591.
20. Tsubota K, Fukagawa K, Fujihara T, et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. Invest Ophthalmol Vis Sci. 1999;40:28-34.
21. Vasania VS, Prasad P, Gill RK, et al. Molecular and cellular characterization of expanded and cryopreserved human limbal epithelial stem cells reveal unique immunological properties. Exp Eye Res. 2011;92: 47-56.
22. Hosoi T, Sasaki M, Baba S, et al. Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem Int. 2009; 54:1-6.
23. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalm ologica. 2003;217:89-98.
24. Ogawa T, Ogasawara A. Effects of pranoprofen on rabbit uveitis. Eye (Lond). 1988;5:1335.
25. Cvenkel B, Kopitar AN, Ihan A. Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Mediators Inflamm. 2010;2010:939602.
26. InaokaM, Kimishima M, Takahashi R, et al. Non-steroidal anti-inflammatory drugs selectively inhibit cytokine production by NK cells and gamma delta T cells. Exp Dermatol. 2006;15:981-990.
27. De La Garza R III, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res. 2003; 977:70-79.
28. Pauly A, Brasnu E, Riancho L, et al. Multiple endpoint analysis of BACpreserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011;17:745-755.
29. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther. 2011;28:501-510.
30. Katz G, Springs CL, Craven ER, et al. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol. 2010;4:1253-1261.
31. Kim JR, Oh TH, Kim HS. Effects of benzalkonium chloride on the ocular surface of the rabbit. Jpn J Ophthalmol. 2011;55:283-293.
32. Lin Z, Liu X, Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis. 2011;17: 257-264.
33. Trocme S, Hwang LJ, Bean GW, et al. The role of benzalkonium chloride in the occurrence of punctate keratitis: A meta-analysis of randomized, controlled clinical trials. Ann Pharmacother. 2010;44: 1914-1921.